You are here: Home » Companies » Results
Business Standard

Cipla posts net profit of Rs 665 cr in Q2, income from ops grows 15%

The company's prescription biz grew 14% YoY supported by continued traction in the Covid portfolio

Topics
Cipla | Q2 results | Pharma industry

Sohini Das  |  Mumbai 

Cipla, Cipla logo, Cipla headquarters
Cipla's trade generics business too, did well along with the consumer health division, driving the overall growth in the domestic market.

Mumbai-headquartered posted a 41 per cent rise in profit after tax for the September quarter riding on strong growth in the Indian market. Income from operations during the quarter grew 15 per cent to Rs 5,038 crore.

posted a net profit of Rs 665 crore. Earnings before income tax, depreciation and amortisation (Ebitda) came in at Rs 1,177 crore, up 29 per cent year on year (YoY).

The company's India business grew 17 per cent YoY as the prescription as well as the trade generics business did well. The prescription business grew 14 per cent YoY supported by continued traction in the Covid portfolio - remdesivir (Cipremi), tocilizumab (Actemra licensed from Roche) and ciplenza (favipiravir). During the quarter, 150,000 patients were supplied with these off-label drugs. Around 95,000 patients were serviced through the 24X7 helpline that the company runs for the Covid-19 drugs. These drugs are off label therapies which means they have emergency use authorisation for treating Covid-19 patients.

ALSO READ: India's largest pharma IPO worth Rs 6,500 cr set to hit market next week

Cipla's trade generics business too, did well along with the consumer health division, driving the overall growth in the domestic market. The company has adopted a One India strategy to leverage greater synergy between prescription, trade generics and over the counter (OTC) consumer brands.

Its two other important markets - (where it is the third largest pharma firm with a private market share of 7 per cent), and the US posted growth during the quarter.

While the business grew 14 per cent YoY (in local currency terms), the posted a 4 per cent YoY growth. launched new products like albuterol and esomeprazole oral suspencsion and DHE nasal spray in the

The company noted that it is working with the to comprehensively address observations received in Goa.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 06 2020. 20:13 IST
RECOMMENDED FOR YOU
.